Mounjaro (tirzepatide): uses, cost, doses and side effects
The short answer
Mounjaro (tirzepatide) is a once-weekly injection from Eli Lilly. It's approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk. The lowest self-pay price is $499 a month through LillyDirect, at every strength.
Key takeaways
- Mounjaro's label covers type 2 diabetes, not weight management. Zepbound is the Lilly tirzepatide brand approved for weight reduction.
- Paying cash? LillyDirect starts at $499 a month, the same starting price at every strength.
- If your commercial insurance covers Mounjaro, the savings card can lower a fill to as little as $25.
- The dose goes up only if more blood sugar control is needed, and your prescriber decides when.
- Missed a dose? If it's been 4 days or less, take it as soon as possible. Otherwise, skip it.
On this page
- What is Mounjaro approved for?
- Mounjaro vs Zepbound: what is the difference?
- What forms does Mounjaro come in?
- How much does Mounjaro cost?
- What doses does Mounjaro come in? (Mounjaro dosage chart)
- What if I miss a dose of Mounjaro?
- What are the side effects of Mounjaro?
- How do I store Mounjaro?
- Does insurance or Medicare cover Mounjaro?
- Where these figures come from
- Frequently asked questions
- Sources
Mounjaro at a glance
| Active ingredient | tirzepatide |
|---|---|
| Maker | Eli Lilly and Company |
| FDA-approved uses |
|
| Forms and strengths |
|
| Medicare GLP-1 Bridge | Not in the Bridge |
| Cheapest verified self-pay | $499 per fill at 15 mg, LillyDirect self-pay (lilly.com) |
| With commercial insurance that covers it | $25 per fill at 15 mg, Manufacturer savings card (commercial insurance, drug covered) (mounjaro.lilly.com) |
| Label | Revised: 8/2026 (DailyMed version 40) |
Mounjaro dose schedule from the label
MounjaroRevised: 8/2026 (DailyMed version 40)
Put it on a calendar with the titration schedule builder. Only your prescriber decides when, and whether, your dose changes.
See every price
Every verified Mounjaro price
| Where you buy | Form · dose | Price | Conditions | Source |
|---|---|---|---|---|
| Manufacturer savings cardcommercial insurance, drug covered | Single-dose pen · All strengths | $25/month | ConditionsCommercial drug insurance that covers Mounjaro. Pay as little as $25 for a 1-, 2- or 3-month fill; maximum savings $150 per 1-month, $300 per 2-month or $450 per 3-month fill, and $1,950 per calendar year; up to 13 fills per year. Month is 28 days and up to 4 pens. Government beneficiaries excluded. Card expires 12/31/2026. | mounjaro.lilly.com |
| Manufacturer savings cardcommercial insurance, drug not covered | Single-dose pen · All strengths | $499/month | ConditionsCommercial drug insurance that does not cover Mounjaro. Pay as low as $499 per 1-month fill (28 days, up to 4 pens); maximum savings $647 per month and $8,411 per calendar year; up to 13 fills per year. Government beneficiaries excluded. Card expires 12/31/2026. | mounjaro.lilly.com |
| LillyDirect self-pay | Single-dose pen · All strengths | $499/month | ConditionsSelf-pay only through LillyDirect; the same $499/month starting price is shown for every strength (2.5, 5, 7.5, 10, 12.5 and 15 mg). Prescription required; additional taxes and fees may apply; purchase terms apply. | lilly.com |
| Mochi Health | Single-dose pen · All strengths | $499/month | Conditions'As low as' price; plus Mochi Health membership ($79/month, first month $0 promo for new subscribers). Medication not included in membership; availability and pricing vary by state. | joinmochi.com |
| Hims & Hers | Single-dose pen · All strengths | $1,899/month | ConditionsMedication only. Requires Hims Weight Loss Membership ($39 first month, then $149/month), billed separately. Cash-pay; insurance not required. Not available in all 50 states. | hims.com |
| List price | Single-dose pen · All strengths | $1,112.16/fill | ConditionsList price (WAC) per fill; one fill is a month's supply of four pens. | pricinginfo.lilly.com |
Mounjaro is Eli Lilly’s brand of tirzepatide for type 2 diabetes. You inject it once a week, and it comes in six strengths that a prescriber steps up over time. This guide sets out what the FDA label (Revised: 8/2026 (DailyMed version 40)) says about its uses, dosing and risks, and what Lilly’s and the providers’ own price pages show about what it costs. Clinical statements come from the label.
What is Mounjaro approved for?
Mounjaro has two approved uses:
- Type 2 diabetes. Along with diet and exercise, to improve blood sugar (glycemic) control in adults and in children 10 years of age and older with type 2 diabetes.
- Cardiovascular risk. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
The safety and effectiveness of Mounjaro haven’t been established in children under 10. The label says it isn’t recommended for people with severe gastroparesis (very slow stomach emptying).
Mounjaro isn’t approved for weight management. That use belongs to a different brand, covered below.
Mounjaro for type 2 diabetes: what the trials showed
The label reports results by trial, each with its own patients and background treatment. HbA1c (A1c), a measure of average blood sugar, is given in percentage points of change from the start of the trial.
- Alone, against placebo (SURPASS-1, 40 weeks). In adults whose diabetes wasn’t controlled with diet and exercise, A1c changed by -1.8 at 5 mg, -1.7 at 10 mg and -1.7 at 15 mg, versus -0.1 with placebo. Body weight changed by -6.3 kg, -7.0 kg and -7.8 kg, versus -1.0 kg with placebo.
- Added to metformin, against semaglutide 1 mg (SURPASS-2, 40 weeks). A1c changed by -2.0, -2.2 and -2.3 on the three Mounjaro doses, versus -1.9 with semaglutide 1 mg.
- Added to basal insulin (SURPASS-5, 40 weeks). A1c changed by -2.1, -2.4 and -2.3, versus -0.9 with placebo.
In the cardiovascular outcomes trial (SURPASS-CVOT, median follow-up 210.1 weeks), Mounjaro was non-inferior to dulaglutide for major cardiovascular events, with a hazard ratio of 0.92. Non-inferior means the trial showed it wasn’t meaningfully worse. Superiority to dulaglutide was not established, so the trial didn’t show it was better. Dulaglutide is sold as Trulicity.
These are group averages from trials. Your own targets and results are a matter for you and your prescriber.
Mounjaro vs Zepbound: what is the difference?
Mounjaro and Zepbound are two Eli Lilly brands that both contain tirzepatide. Both are injected once weekly, both come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, and both start at 2.5 mg. The labels differ in what the medicine is approved to treat:
- Mounjaro: type 2 diabetes (blood sugar control, and cardiovascular risk reduction in adults at high risk).
- Zepbound: weight reduction and long-term maintenance in adults with obesity or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity.
Three practical things follow from that.
Insurance treats them as different drugs. A plan may cover Mounjaro for type 2 diabetes and exclude Zepbound for weight management, or apply different prior authorization rules to each. The Mounjaro savings card requires a prescription for an approved use consistent with the FDA label.
The prices are different. Mounjaro’s self-pay price through LillyDirect is $499 a month at every strength. Zepbound’s self-pay vial and KwikPen run from $299 to $449 depending on dose and on refilling on time.
They aren’t used together. The Zepbound label says that using it with other tirzepatide-containing products isn’t recommended.
Which brand you’re prescribed follows from your diagnosis. If you’re changing between GLP-1 medicines, the switching planner shows what each label says about where to start. It doesn’t convert doses.
What forms does Mounjaro come in?
The label lists four forms, each in all six strengths:
- Single-dose pen. A prefilled pen that delivers one dose. A carton holds four pens, which is one fill. Every Mounjaro price on this page is for this form.
- Single-dose vial. One dose per vial, drawn up with a syringe. The label says to use a syringe suited to the dose (for example a 1 mL syringe) and a new syringe and needle for every injection.
- KwikPen. One pen that holds four weekly doses. The label says the KwikPen isn’t recommended for self-administration by children or by people who are visually impaired. It also says a KwikPen must never be shared between patients, even if the needle is changed.
- Multi-dose vial. Four weekly doses per vial.
The label asks prescribers to tell you which form you’ll get and to make sure you’re trained on it, including if it changes. A healthcare provider should show you how to prepare and inject your dose before the first time.
How much does Mounjaro cost?
The Mounjaro single-dose pen has four published prices:
- List price: $1,112.16 per fill (four pens). This is the full price before any discount. What you pay largely depends on your prescription drug insurance.
- LillyDirect self-pay: starting at $499 a month, the same starting price shown for every strength from 2.5 mg to 15 mg. This is a cash price for people not using insurance, and taxes and fees may be added.
- Savings card, insurance covers Mounjaro: as little as $25 for a 1-month, 2-month or 3-month fill.
- Savings card, insurance doesn’t cover Mounjaro: $499 for a 1-month fill.
Unlike Zepbound, Mounjaro’s self-pay price doesn’t change with the dose. A fill is 28 days, so a year is 13 fills: $6,487 at the LillyDirect price.
Our Mounjaro cost guide goes through each route, and the cost calculator prices any of them for a full year.
The Mounjaro savings card
The card is for people with commercial (private or employer) drug insurance. If you’re enrolled in Medicare, Medicaid, TRICARE, VA or another government program, you can’t use it.
If your plan covers Mounjaro, the card brings a fill down to as little as $25. Lilly limits how much it pays per fill and per calendar year, and you can use the card for up to 13 fills a year. So a plan with a high deductible can leave you paying more than the headline amount. If your commercial plan doesn’t cover Mounjaro, the card sets a 1-month fill at $499, the same as the LillyDirect self-pay price. The card expires on 12/31/2026. Our savings card guide compares the manufacturer cards side by side.
Telehealth programs
Some telehealth providers prescribe Mounjaro and add a membership fee to the medicine price. Their published starting prices for the Mounjaro pen vary widely: one lists it from $499 a month and another from $1,899, each before membership. The tables on this page add the membership so you can compare the true monthly cost.
What doses does Mounjaro come in? (Mounjaro dosage chart)
Mounjaro comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Each is one weekly injection. The dose ladder on this page is the chart. In words, the label says:
- Start at 2.5 mg once weekly.
- If more blood sugar control is needed, increase in 2.5 mg steps, after at least 4 weeks on the current dose.
- Maximum: 15 mg once weekly in adults, and 10 mg once weekly in children 10 and older.
The Mounjaro label doesn’t name particular strengths as maintenance doses (doses you stay on) the way the Zepbound label does. The dose goes up only if more blood sugar control is needed, so some people stay on a lower strength. Your prescriber decides when and whether to step up. The titration schedule tool lays the steps out by date.
How do you take Mounjaro?
Inject Mounjaro under the skin of your abdomen or thigh. Another person can inject it in the back of your upper arm. Rotate the injection site with each dose. You can take it at any time of day, with or without meals.
If you also use insulin, the label says to give the two as separate injections and never mix them. They can go in the same body region, but not right next to each other.
What if I miss a dose of Mounjaro?
The label’s rule turns on 4 days:
- If 4 days (96 hours) or less have passed since the missed dose, take it as soon as possible.
- If more than 4 days have passed, skip the missed dose and take the next dose on your regularly scheduled day.
Either way, you then go back to your regular once-weekly schedule. You can also change your weekly injection day if needed, as long as the two doses are at least 3 days (72 hours) apart.
The missed dose tool works this out from your dates. For a longer gap, ask your prescriber how to restart.
What are the side effects of Mounjaro?
Most reported side effects involve the stomach and bowel. In the label’s pool of placebo-controlled trials in adults with type 2 diabetes, gastrointestinal reactions occurred in 37.1 percent of people on 5 mg, 39.6 percent on 10 mg and 43.6 percent on 15 mg, compared with 20.4 percent on placebo. In the 5 mg, 10 mg and 15 mg groups versus placebo:
- Nausea: 12, 15 and 18 percent, versus 4 percent.
- Diarrhea: 12, 13 and 17 percent, versus 9 percent.
- Decreased appetite: 5, 10 and 11 percent, versus 1 percent.
- Vomiting: 5, 5 and 9 percent, versus 2 percent.
- Constipation: 6, 6 and 7 percent, versus 1 percent.
More people stopped treatment because of gastrointestinal reactions on Mounjaro (3.0, 5.4 and 6.6 percent across the three doses) than on placebo (0.4 percent). The full table is on this page.
Low blood sugar
In the label’s 40-week trial of Mounjaro used alone, blood glucose below 54 mg/dL was reported by 0 percent of people on each Mounjaro dose and 1 percent on placebo. The label warns that the risk may be higher when Mounjaro is combined with insulin or with a sulfonylurea. In a trial of up to 104 weeks in which Mounjaro was given with a sulfonylurea, hypoglycemia (glucose below 54 mg/dL) occurred in 13.8%, 9.9% and 12.8% of patients on 5 mg, 10 mg and 15 mg. The label says your prescriber should consider reducing the dose of the sulfonylurea or insulin when Mounjaro is started.
The boxed warning: thyroid C-cell tumors
Mounjaro carries a boxed warning, the strongest kind the FDA requires. In male and female rats, tirzepatide caused thyroid C-cell tumors. It isn’t known whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in people. For that reason, Mounjaro is contraindicated, meaning it must not be used, in anyone with a personal or family history of MTC, or with multiple endocrine neoplasia syndrome type 2 (MEN 2). It’s also contraindicated in people with a known serious hypersensitivity (allergic reaction) to tirzepatide or any of its ingredients.
Other warnings on the label
The label also warns about acute pancreatitis, serious allergic reactions, acute kidney injury caused by dehydration from vomiting or diarrhea, severe gastrointestinal reactions, worsening of diabetic retinopathy in people with a history of it, acute gallbladder disease, and pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation. Tell any clinician planning a procedure that you take Mounjaro.
Two more points from the label:
- Pregnancy. Mounjaro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Birth control pills. Mounjaro may reduce the effect of oral hormonal contraceptives. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
How do I store Mounjaro?
Store Mounjaro in the refrigerator at 2°C to 8°C (36°F to 46°F), in the original carton to protect it from light. Don’t freeze it, and don’t use it if it has been frozen.
- Single-dose pens and single-dose vials can be stored unrefrigerated, at no more than 30°C (86°F), for up to a total of 21 days. After that, they must be thrown away.
- An unopened KwikPen or multi-dose vial kept at room temperature (up to 30°C or 86°F) is thrown away after 30 days.
- An opened KwikPen or multi-dose vial is thrown away after a total of 30 days at room temperature, 30 days after first use, or after 4 weekly doses, even if there is medicine left.
Before each injection, look at the medicine. The label says it should be clear and colorless to slightly yellow.
Does insurance or Medicare cover Mounjaro?
Commercial insurance
Because Mounjaro is a diabetes medicine, many commercial plans list it, often with conditions: prior authorization (the plan’s approval before it pays), proof of a type 2 diabetes diagnosis, or a requirement to try another medicine first. Plans differ, so call the number on your insurance card. Ask whether Mounjaro is on your formulary (the plan’s list of covered drugs), what tier it’s on, and what the plan needs from your prescriber.
If the plan covers it, the savings card can lower your share. If a request is denied, your prescriber can supply more information or appeal. The appeal letter generator drafts a letter to start from.
Medicare
CMS states that type 2 diabetes is an indication eligible for Part D coverage, and that people with a GLP-1 prescription for a Part D covered use should keep getting it through their Part D plan. So for Mounjaro, Medicare coverage runs through your Part D plan’s formulary and rules, and your cost depends on the plan.
Mounjaro isn’t one of the drugs in the Medicare GLP-1 Bridge. The Bridge is a temporary program for weight management, and people with type 2 diabetes aren’t eligible for it. Our Medicare hub explains how Part D and the Bridge fit together.
If you have Medicare or other government coverage, you can’t use the Lilly savings card.
Where these figures come from
Each price comes from the manufacturer’s or provider’s own page, as described in how we verify prices. Label facts come from the FDA label. All of the prices feed the GLP-1 Price Index.
Where to get Mounjaro
1. Manufacturer savings card (commercial insurance, drug covered)
$25 per fill at 15 mg
2. LillyDirect self-pay
$499 per fill at 15 mg
Source: lilly.comGo to the program page
3. Manufacturer savings card (commercial insurance, drug not covered)
$499 per fill at 15 mg
Ranked by cost only. Manufacturer and government programs never pay us. To see every option for your situation, try the cheapest-path quiz.
Frequently asked questions
What is Mounjaro used for?
Mounjaro has two FDA-approved uses. Along with diet and exercise, it's used to improve blood sugar control in adults and children 10 years and older with type 2 diabetes. It's also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them. Its label doesn't include weight management.
How much does Mounjaro cost a month?
Mounjaro's list price is $1,112.16 per fill of four pens. If you pay cash through LillyDirect, it's $499 a month at every strength. If your commercial insurance covers Mounjaro, the savings card can lower a fill to as little as $25. What you pay through insurance alone depends on your plan.
How does the Mounjaro savings card work?
The card is for people with commercial drug insurance and a prescription for an approved use. If your plan covers Mounjaro, you pay as little as $25 for a 1-month, 2-month or 3-month fill. If your plan doesn't cover it, the card sets the price at $499 for a 1-month fill. Government beneficiaries are excluded, and the card expires on 12/31/2026.
What doses does Mounjaro come in?
Mounjaro comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The label's starting dose is 2.5 mg once weekly. If more blood sugar control is needed, the dose goes up in 2.5 mg steps after at least 4 weeks on the current dose. The maximum is 15 mg once weekly in adults and 10 mg once weekly in children.
Is Mounjaro the same medicine as Zepbound?
Both are Eli Lilly brands that contain tirzepatide, in the same six strengths, injected once weekly. Their labels differ: Mounjaro is approved for type 2 diabetes, and Zepbound for weight reduction and for obstructive sleep apnea in adults with obesity. They have separate prices and savings programs, and the Zepbound label says not to combine it with other tirzepatide products.
What if I miss a dose of Mounjaro?
The label says to take the missed dose as soon as possible within 4 days (96 hours) after it was due. If more than 4 days have passed, the label says to skip it and take the next dose on your regularly scheduled day. You then go back to your usual weekly schedule. If you've missed several doses, ask your prescriber.
What are the most common side effects of Mounjaro?
In the label's pooled placebo-controlled trials in adults with type 2 diabetes, the reactions reported most often were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion) and abdominal pain. Nausea was reported by 12 to 18 percent of people on Mounjaro, depending on dose, compared with 4 percent on placebo. Mounjaro also carries a boxed warning about thyroid C-cell tumors.
Does Medicare cover Mounjaro?
Type 2 diabetes is a use that Medicare Part D can cover, so coverage comes through your Part D plan and its formulary, and your cost depends on the plan. Mounjaro isn't part of the Medicare GLP-1 Bridge, which is for weight management and isn't open to people with type 2 diabetes. If you're on Medicare, you can't use the Lilly savings card.
Is Mounjaro approved for weight loss?
No. Mounjaro's label covers type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes, and it doesn't include weight management. Zepbound, another Eli Lilly brand that contains tirzepatide, is the one approved for weight reduction in adults with obesity, or with overweight and a weight-related condition. In the label's 40-week trial of Mounjaro used alone in adults with type 2 diabetes, body weight changed by -6.3 kg to -7.8 kg, versus -1.0 kg with placebo.
Sources (34)
- 1.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose.”
- 2.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Administer MOUNJARO once weekly, any time of day, with or without meals.”
- 3.FDA label (DailyMed): Mounjaro Medication Guide (in the prescribing information)
“Your healthcare provider should show you how to prepare and inject your dose of MOUNJARO before injecting for the first time.”
- 4.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
- 5.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.”
- 6.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 7.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.”
- 8.FDA label (DailyMed): Mounjaro prescribing information, section 16.2
“Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”
- 9.FDA label (DailyMed): Mounjaro prescribing information, section 16.2
“If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days. Discard the single-dose pen or single-dose vial after a total of 21 days at room temperature.”
- 10.FDA label (DailyMed): Mounjaro prescribing information, section 16.2
“Do not freeze MOUNJARO. Do not use MOUNJARO if frozen. Protect MOUNJARO from heat and light. Store MOUNJARO in the original carton to protect from light.”
- 11.FDA label (DailyMed): Mounjaro prescribing information, section 16.2
“Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F). The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator. If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.”
- 12.FDA label (DailyMed): Mounjaro prescribing information, section 16.2
“Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”
- 13.FDA label (DailyMed): Mounjaro prescribing information, section 8.1
“MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
- 14.FDA label (DailyMed): Mounjaro prescribing information, section 8.3
“Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 15.FDA label (DailyMed): Mounjaro prescribing information, section 7.1
“When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
- 16.FDA label (DailyMed): Mounjaro prescribing information, section 6.1
“In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.”
- 17.FDA label (DailyMed): Mounjaro prescribing information, section 14.2, Table 4
“Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise. HbA1c (%) - Change at Week 40: Placebo: -0.1; MOUNJARO 5 mg: -1.8; MOUNJARO 10 mg: -1.7; MOUNJARO 15 mg: -1.7”
- 18.FDA label (DailyMed): Mounjaro prescribing information, section 14.2, Table 4
“Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise. Body Weight (kg) - Change at Week 40: Placebo: -1.0; MOUNJARO 5 mg: -6.3; MOUNJARO 10 mg: -7.0; MOUNJARO 15 mg: -7.8”
- 19.FDA label (DailyMed): Mounjaro prescribing information, section 14.3, Table 5
“Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin. HbA1c (%) - Change at Week 40: Semaglutide 1 mg: -1.9; MOUNJARO 5 mg: -2.0; MOUNJARO 10 mg: -2.2; MOUNJARO 15 mg: -2.3”
- 20.FDA label (DailyMed): Mounjaro prescribing information, section 14.4, Table 8
“Table 8: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus. HbA1c (%) - Change at Week 40: Placebo: -0.9; MOUNJARO 5 mg: -2.1; MOUNJARO 10 mg: -2.4; MOUNJARO 15 mg: -2.3”
- 21.FDA label (DailyMed): Mounjaro prescribing information, section 14.6
“Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
- 22.FDA label (DailyMed): Mounjaro prescribing information, section 5.6
“MOUNJARO is not recommended in patients with severe gastroparesis.”
- 23.FDA label (DailyMed): Mounjaro prescribing information, section 8.4
“The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
- 24.FDA label (DailyMed): Mounjaro prescribing information, section 4
“MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
- 25.FDA label (DailyMed): Mounjaro prescribing information, section 4
“MOUNJARO is contraindicated in patients with: Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.”
- 26.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 27.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
